U.S. markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.59+0.02 (+0.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.57
Open8.39
Bid8.54 x 1100
Ask9.53 x 1100
Day's Range8.13 - 8.70
52 Week Range7.01 - 22.39
Volume256,322
Avg. Volume87,114
Market Cap280.718M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation
    Benzinga

    Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation

    The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to report full data from the ReDUX4 Phase 2b trial at the virtual FSHD International Research Congress to be held next month. Losmapimod previously received Orphan Drug Designation for FSHD. Losmapimod is a selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor exclusively in-licensed from GlaxoSmithKline plc (NYSE: GSK). Evofem Biosciences Inc's (NASDAQ: EVFM) EVO100 to prevent urogenital gonorrhea in women also received the Fast Track tag from the FDA. Phase 3 trial of EVO100 for prevention of chlamydia and gonorrhea in women is currently enrolling. The Company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022, with potential marketing application submission by the end of 2022. EVO100 previously received the FDA Fast Track designation for the prevention of chlamydia in women. It was also designated as a Qualified Infectious Disease Product for the prevention of gonorrhea in women. Price Action: FULC shares closed 0.38% lower at $10.40, while EVFM shares closed 0.81% higher at $1.25 on Wednesday. See more from BenzingaClick here for options trades from BenzingaVBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious DiseasesFDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • News Flash: Analysts Just Made A Huge Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
    Simply Wall St.

    News Flash: Analysts Just Made A Huge Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

    Shareholders in Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) may be thrilled to learn that the analysts have just...

  • A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns
    Simply Wall St.

    A Look At Fulcrum Therapeutics' (NASDAQ:FULC) Share Price Returns

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...